Galactose
Approved medicineAlso known as D(+)-Galactose, D-Galactose.
Recent clinical, regulatory, research and industry developments relating to this drug.
Beyond galactose deficiency: redefining pathogenic IgA in IgA nephropathy
Novel Therapies for Resistant Focal Segmental Glomerulosclerosis
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- BMC nephrology1
- Experimental brain research1
- International journal of molecular sciences1
- Wei C2
- Gassman J1
- Gipson DS1
- Herreshoff E1
- Jin Y1
- Li X1
- Radeva M1
- Reiser J1
- Albert Einstein College of Medicine1
- Boston Children's Medical Center1
- Children's Mercy Hospital1
- Cleveland Clinic Foundation1
- Kansas City Veteran's Administration Medical Center1
- NYU Langone Medical Center1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials